key: cord-1050986-bzbzbmx6
authors: Collienne, Maike; Arnold, Dirk
title: Treating GI cancer during the COVID-19 pandemic in Europe
date: 2020-07-09
journal: Clin Colorectal Cancer
DOI: 10.1016/j.clcc.2020.07.004
sha: 65321666340aee53168b1a575df9a6afd0b5982f
doc_id: 1050986
cord_uid: bzbzbmx6

nan

In Europe, the first cases of COVID-19 were reported in several countries (e.g. Italy, Germany, Spain, France, UK) in January 2020. U p through March 2020, COVID-19 had spread to every European country, and the WHO declared COVID-19 a pandemic. As of June 3, 2020 1,981,431 infections and 176,269 deaths due to COVID-19 had been registered in Europe (European Centre for Disease Prevention and Control 2020).

Since the start of the pandemic, treating cancer has become challenging. To protect patients and to provide the best care possible, the normal routines had to be changed. Many consultations normally conducted in person were postponed or done remotely, patient treatment plans were re-evaluated, and clinical trials continued albeit under difficult conditions.

As well-defined plans for a pandemic were lacking in many hospitals and health care systems all around Europe, different strategies against COVID-19 had to be implemented. The specific strategies depended on the spread and intensity of the virus and the pre-existing health care systems as follows:

In Italy, the first European country with a huge amount of cases, the government reorganized the health care system aiming to establish a separation between COVID-19 and COVID-19 free hospitals. In Northern Italy (i.e. Lombardy region), cancer care was coordinated on a hub-and-spoke basis: cancer centers were defined as hubs and general hospitals as spokes. In consequence, patients could get their investigations and in part their systemic treatment nearby their residency instead of commuting to (more centralized) cancer centers, reducing need for travelling. Results and further recommendations were discussed remotely. Furthermore, systemic therapies were switched from intravenous to oral administration and treatment cycles were lengthened or postponed, when deemed appropriate (Brandes, Ardizzoni et al. 2020 , Curigliano 2020 , Fratino, Procopio et al. 2020 .

Besides protecting cancer patients, the health care staff also had to be shielded from COVID-19. The availability of diagnostic swabs for health care workers was very limited at the beginning. Furthermore, asymptomatic cases, who put staff at risk, were (also) detected in designated COVID-19 free hospitals. In a survey of 12 medical oncology departments in the Emilia Romagna region, 6.9 % of staff members were infected with COVID-19 (Brandes, Ardizzoni et al. 2020) . However, most of the oncologists could continue working in their respective departments (Indini, Aschele et al. 2020 ).

In the UK, the National Healthcare System (NHS) established cancer centers as hubs (similar to the Italian design) declared as COVID-19 free hospitals, in London, Manchester and Leeds. Furthermore, the NHS and private hospitals worked in collaboration to achieve the best cancer care possible. However, screening services were, as in many other countries in Europe, placed on hold in Wales, Scotland, and Northern Ireland. Cancer Research UK estimated that approximately 200,000 screenings per week were not done and thus, more than approximately 10,000 cancer diagnosis per month were missed across the UK (Hiom 2020 ). In addition, risk assessments for cancer cases were centrally collected and published to help general practitioners in differentiating between low-and high-risk situations (Cancer Research UK 2020) . Moreover, to directly support patients, the NHS contacted those patients assessed as high risk to offer assistance in medical care and daily life.

In Spain, different health care systems exist in parallel, which were already well connected before the pandemic. As a consequence, sharing information between cancer centers, general hospitals, and primary physicians was rather simple. Hence, oncologists were able to guide their patients well informed through this crisis and had always the chance to react to changes quickly.

As in many other countries, elective surgery was reduced or stopped due to the lack of ICU capacities. Under these circumstances, surgical procedures were postponed, and neoadjuvant treatments established, if appropriate.

Clinical trials specifically focused on COVID-19 were preferentially processed and launched to assess possible drugs against COVID-19 (Ong 2020).

In Germany, the medical oncology departments are generally situated within general hospitals. Therefore, highest priority was to separate cancer patients from all other patients, in order to reduce the risk of COVID-19 spread. Hence, diagnostic swabs were established in many hospitals at an early point of the pandemic.

Fortunately, the case rate in Germany was not as high as in Italy or Spain, so treatment approaches (systemic treatment, radiotherapy, surgical procedures) were continued on. In tumor boards, decisions on individual concepts were made with special regard to each cancer type, its standard therapy, and COVID-19, but generally, there were only a few processes and standards that had to be adapted.

In summary, a tremendous heterogeneity of cancer care exists across Europe. Beside nationwide recommendations of treating GI cancer during the pandemic, the European Society of Medical Oncology has published guidelines for different cancer types stratifying high, intermediate, and low risk. Moreover, detailed information about cancer and COVID-19 in Europe are expected from the international collaborative registry ESMO-CoCARE (European Society for Mecial Oncology 2020).

Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of Italy

Cancer decision support tools overview

How to Guarantee the Best of Care to Patients with Cancer During the COVID-19 Epidemic: The Italian Experience

COVID-19 situation update worldwide

ESMO-CoCARE Registry

Coronavirus: Older Persons With Cancer in Italy in the COVID-19 Pandemic

How coronavirus is impacting cancer services in the UK

Reorganisation of medical oncology departments during the novel coronavirus disease-19 pandemic: a nationwide Italian survey

COVID-19 lesson from Spain: Like the U.S., we failed to take this seriously before it came to us -we have to learn